Bristol Myers Squibb shares rose Friday, a day after its schizophrenia drug was approved for use by the Food and Drug ...

The U.S. Food and Drug Administration (FDA) on Thursday approved Bristol Myers Squibb’s (BMY) highly anticipated ...

The FDA approves BMY's differentiated schizophrenia treatment for adults and broadens its diverse portfolio. Shares gain.

Bristol Myers trades higher after the FDA approves an oral medication for schizophrenia in adults, fiscal fourth-quarter ...

Analyst Evan Seigerman from BMO Capital maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) and increased the price ...

Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely ...

The FDA has approved a first-in-class antipsychotic that targets cholinergic receptors without blocking dopamine receptors.

The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in ...

U.S. stock indexes are drifting around their records Friday as hopes hold that the economy can pull off the rare feat of getting painfully high inflation under control without a recession.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AbbVie (ABBV – Research Report), ACADIA ...